You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
麗珠醫藥(01513.HK):麗珠單抗與華南疫苗簽署流感重組蛋白疫苗項目專利及技術轉讓協議
格隆匯 12-09 19:35

格隆匯12月9日丨麗珠醫藥(01513.HK)公吿,近日,公司控股子公司珠海市麗珠單抗生物技術有限公司(麗珠單抗)與廣東華南疫苗股份有限公司(華南疫苗)簽署了《流感重組蛋白疫苗項目專利及技術轉讓協議》。根據協議約定,華南疫苗擬將基於項目技術開發的最終銷售形態的三價流感重組蛋白疫苗及/或四價流感重組蛋白疫苗的項目權利轉讓給麗珠單抗,麗珠單抗需向華南疫苗支付相應的專利及技術轉讓費(包括首付款、開發里程碑款及銷售里程碑款)及銷售提成。目標產品為流感重組蛋白疫苗,已經獲得國家藥品監督管理局的批准開展預防流行性感冒的臨牀試驗。

協議生效後,麗珠單抗應向華南疫苗支付技術轉讓費用總額最高不超過 21,000.00 萬元人民幣(包括首付款、開發里程碑款和銷售里程碑款)。

本次項目引進可進一步豐富公司創新藥領域的產品佈局,同時強化公司疫苗技術平台的競爭力,有利於提高公司的綜合實力,符合公司中長期創新發展的戰略佈局。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account